NextCure (NXTC) Stock Price, News & Analysis

Company Overview

NextCure, Inc. (NASDAQ: NXTC) is a clinical‐stage biotechnology company dedicated to discovering and developing immuno‐oncology therapies that harness the body’s immune system to fight cancer. Utilizing its proprietary immune modulation discovery platforms, NextCure identifies novel targets and advances both antibody and small‐molecule candidates designed to either stimulate antitumor immunity or counteract tumor‐induced immune suppression. The company’s scientific approach rests on deep insights into the molecular pathways that regulate immune cell function within the tumor microenvironment.

The company’s pipeline comprises multiple clinical and preclinical programs. Lead clinical candidate NX‐1607 is an antibody targeting a novel immune checkpoint receptor, currently undergoing dose‐escalation studies in patients with advanced solid tumors. NextCure has also initiated early‐stage trials for NX‐2127, a targeted protein degrader aimed at key immune regulatory proteins, and NX‐5948, a small molecule designed to modulate innate immune pathways. Parallel preclinical efforts explore next-generation therapies for both oncology and select inflammatory diseases.

Founded in 2011 and headquartered in Beltsville, Maryland, NextCure has built a multidisciplinary leadership team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s executives and advisory board members bring backgrounds from leading pharmaceutical and biotech organizations, supporting its translational research and clinical trial activities. NextCure operates research facilities in the U.S. and maintains strategic collaborations with global pharmaceutical partners to accelerate the development of its immuno‐oncology candidates.

NextCure’s mission is to transform cancer treatment by advancing therapies that precisely engage the immune system against tumors, while minimizing off‐target effects. With a robust platform, an expanding pipeline and collaborative alliances, the company aims to deliver new treatment options for patients with hard‐to‐treat malignancies and to broaden the impact of immuno‐oncology across multiple tumor types.

Key Stats

• Today's Range: $4.95 to $5.37
• 50-Day Range: $4.74 to $8.17
• 52-Week Range: $2.69 to $21.48
• Volume: 29,253 shs
• Average Volume: 11,588 shs
• Market Capitalization: $13.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

NextCure Stock Analysis - MarketRank™

NextCure scored higher than 87% of companies evaluated by MarketBeat, and ranked 134th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NextCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

NextCure has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

Price to Book Value per Share Ratio

NextCure has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently increased by 14.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NextCure does not currently pay a dividend.

Dividend Growth

NextCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.08

Percentage of Shares Shorted

1.40% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently increased by 14.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.48

News Sentiment

NextCure has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NextCure this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added NextCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NextCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NXTC Stock Analysis - Frequently Asked Questions

How have NXTC shares performed this year?

NextCure's stock was trading at $9.2520 at the start of the year. Since then, NXTC stock has decreased by 46.1% and is now trading at $4.99.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings results on Thursday, May, 1st. The company reported ($4.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.80) by $0.12.

When did NextCure's stock split?

NextCure shares reverse split before market open on Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did NextCure IPO?

NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NXTC
• CIK: 1661059
• Web: www.nextcure.com
• Phone: (240) 399-4900
• Fax: N/A
• Employees: 90
• Year Founded: 2015

Price Target and Rating

• Average Price Target for NextCure: $33.00
• High Price Target: $48.00
• Low Price Target: $15.00
• Potential Upside/Downside: +561.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($21.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.16%
• Return on Assets: -58.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.26
• Quick Ratio: 10.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $28.06 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 2,680,000
• Free Float: 2,196,000
• Market Cap: $13.37 million
• Optionable: Optionable
• Beta: 1.06